Bromide

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024

LONDON and RALEIGH, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2023, and provides a corporate update.

Key Points: 
  • The debt facility provides non-dilutive capital and further financial flexibility to support Verona Pharma’s continued growth, including the commercialization of ensifentrine.
  • Net loss: Net loss was $14.1 million for the fourth quarter ended December 31, 2023 (Q4 2022: net loss $10.5 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Thursday, February 29, 2024, to discuss the fourth quarter and full year 2023 financial results and the corporate update.
  • An electronic copy of the fourth quarter and full year 2023 results press release will also be made available today on the Company’s website.

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 3, Status: Authorised

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023

LONDON and RALEIGH, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.

Key Points: 
  • PDUFA Target Action Date of June 26, 2024
    Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT
    LONDON and RALEIGH, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.
  • Net loss: Net loss was $14.7 million for the third quarter ended September 30, 2023 (Q3 2022: $15.6 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 1:00 p.m. GMT on Thursday, November 2, 2023, to discuss the third quarter 2023 financial results and the corporate update.
  • An electronic copy of the third quarter 2023 results press release will also be made available today on the Company’s website.

Explainer: the philosophy of Jean-Jacques Rousseau is profoundly contemporary

Retrieved on: 
Monday, September 25, 2023

No account of the modern era – not just modern thought – could ignore him.

Key Points: 
  • No account of the modern era – not just modern thought – could ignore him.
  • But like any major thinker, there are risks in summaries – some of which give us clues about Rousseau himself.
  • Although he is known as a social and political philosopher, Rousseau’s creative output does not resemble that of a contemporary “theorist”.
  • These are now conventional tropes, but they were only emerging at the time Rousseau was writing.

Natural or artificial

    • Rousseau had shot to fame a decade earlier, after winning an essay competition advertised in the literary magazine Mercure de France.
    • Where much philosophical discussion had been centred around the distinction between the “natural” and the “supernatural”, Rousseau opposed the natural to the artificial.
    • He argued that what we ordinarily think of as civilisational progress creates – and then aims to satisfy – new and artificial vices, serving our vanity and not our natural needs.
    • In fact, he proposed there were many good reasons to think they were greater in both.
    • Read more:
      Guide to the Classics: Voltaire’s Candide — a darkly satirical tale of human folly in times of crisis

Society and inequality

    • Developing these ideas, in 1754, Rousseau wrote his Discourse on the Origin and Basis of Inequality Among Men.
    • In it, he attempted a thought experiment which imagined what humans may have been like in a “pre-civilisational” state.
    • Rousseau was aware that this act of imagination was speculative and he could not be sure of its results.
    • He held that inequality was artificial.

Education and politics

    • The first was the institution of a new kind of education; the second was reorienting politics towards a new moral foundation.
    • In Émile, or On Education (1862), Rousseau wrote a treatise on education in the form of a bildungsroman – the first and likely the last of its kind.
    • He sought to outline the conditions of a good education, which he thought should be based on lived experience and the development of individual character, not rote learning, mechanical memorisation, or even the reading of books.
    • As for moral education, young people should learn about the consequences of their actions.
    • Rousseau’s terminology has oriented discussions of morality, self-development and politics from the 18th century to the counterculture of the 1960s, the New Age movement of the 1980s, and beyond.

Deism and human nature

    • According to Rousseau, we know what we know of God from Nature and Reason alone.
    • In Rousseau, Judge of Jean-Jacques (1776), Rousseau addresses this question directly, and in typically Rousseauian fashion:
      whence could the painter and apologist of human nature have taken his model, if not from his own heart?
    • He has described this nature just as he felt it within himself.
    • whence could the painter and apologist of human nature have taken his model, if not from his own heart?
    • He has described this nature just as he felt it within himself.

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 16, 2023

MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced results for the three and six months ended June 30, 2023 and provided a business update.

Key Points: 
  • “Our second quarter was a transformative period for Baudax Bio, during which we announced positive top-line results from our Phase 2 BX1000 trial and capped off with our acquisition of TeraImmune,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio.
  • The acquisition was unanimously approved by the Board of Directors of Baudax Bio and the Board of Directors of TeraImmune.
  • Financial Results for the Three Months Ended June 30, 2023
    As of June 30, 2023, Baudax Bio had cash and cash equivalents of $1.4 million.
  • Baudax Bio reported net loss from continuing operations of $(14.7) million, or $(4.08) per share, for the six months ended June 30, 2023.

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Retrieved on: 
Monday, June 12, 2023

"With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."

Key Points: 
  • "With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."
  • Both neostigmine methylsulfate and glycopyrrolate have been approved in the U.S. as single, active ingredient drug products.
  • Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes.
  • This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error—all of which support quality patient care.

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Retrieved on: 
Monday, June 12, 2023

"With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."

Key Points: 
  • "With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."
  • Both neostigmine methylsulfate and glycopyrrolate have been approved in the U.S. as single, active ingredient drug products.
  • Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes.
  • This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error—all of which support quality patient care.

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

Retrieved on: 
Wednesday, June 7, 2023

Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.

Key Points: 
  • Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.
  • The BX1000 Phase 2 surgery trial was a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a completed clinical trial of 80 adult patients who had elective surgery utilizing total intravenous anesthesia.
  • A total of 81 patients were randomized to the four treatment groups.
  • Additionally, the clinical trial evaluated the safety and tolerability profile of BX1000 and rocuronium in this patient population.